
|Slideshows|June 28, 2018
ADA 2018: CV Benefits of SGLT-2 Inhibitors
Author(s)Kenneth J. Bender, PharmD, MA
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
2
FDA Accepts Extended Duration sNDA for Miudella Hormone-Free IUD
3
Why Prostate Cancer Screening Belongs in Primary Care
4
Endocrine Society Calls for Obesity Treatment Goals Beyond Weight Loss
5





















































































































































